Proteasome inhibitor

WikiDoc Resources for Proteasome inhibitor

Articles

Most recent articles on Proteasome inhibitor

Most cited articles on Proteasome inhibitor

Review articles on Proteasome inhibitor

Articles on Proteasome inhibitor in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Proteasome inhibitor

Images of Proteasome inhibitor

Photos of Proteasome inhibitor

Podcasts & MP3s on Proteasome inhibitor

Videos on Proteasome inhibitor

Evidence Based Medicine

Cochrane Collaboration on Proteasome inhibitor

Bandolier on Proteasome inhibitor

TRIP on Proteasome inhibitor

Clinical Trials

Ongoing Trials on Proteasome inhibitor at Clinical Trials.gov

Trial results on Proteasome inhibitor

Clinical Trials on Proteasome inhibitor at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Proteasome inhibitor

NICE Guidance on Proteasome inhibitor

NHS PRODIGY Guidance

FDA on Proteasome inhibitor

CDC on Proteasome inhibitor

Books

Books on Proteasome inhibitor

News

Proteasome inhibitor in the news

Be alerted to news on Proteasome inhibitor

News trends on Proteasome inhibitor

Commentary

Blogs on Proteasome inhibitor

Definitions

Definitions of Proteasome inhibitor

Patient Resources / Community

Patient resources on Proteasome inhibitor

Discussion groups on Proteasome inhibitor

Patient Handouts on Proteasome inhibitor

Directions to Hospitals Treating Proteasome inhibitor

Risk calculators and risk factors for Proteasome inhibitor

Healthcare Provider Resources

Symptoms of Proteasome inhibitor

Causes & Risk Factors for Proteasome inhibitor

Diagnostic studies for Proteasome inhibitor

Treatment of Proteasome inhibitor

Continuing Medical Education (CME)

CME Programs on Proteasome inhibitor

International

Proteasome inhibitor en Espanol

Proteasome inhibitor en Francais

Business

Proteasome inhibitor in the Marketplace

Patents on Proteasome inhibitor

Experimental / Informatics

List of terms related to Proteasome inhibitor

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

## Overview

[edit | edit source]

File:Bortezomib.svgChemical structure of bortezomib, the first proteasome inhibitor approved for use.

Proteasome inhibitors are drugs that block the action of proteasomes, cellular complexes that break down proteins, like the p53 protein. Proteasome inhibitors are being studied in the treatment of cancer. In 2003, bortezomib was the first proteasome inhibitor to be approved for use in the U.S.

A derivative of epigallocatechin-3-gallate has been proposed as another proteasome inhibitor.[1]

## References

[edit | edit source]

1. ↑ Osanai K, Landis-Piwowar KR, Dou QP, Chan TH (2007). "A para-amino substituent on the D-ring of green tea polyphenol epigallocatechin-3-gallate as a novel proteasome inhibitor and cancer cell apoptosis inducer". doi:10.1016/j.bmc.2007.05.041. PMID 17544279.CS1 maint: Multiple names: authors list (link)

Template:SIB Template:WH Template:WS